Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Ticagrelor Does not Impact Patient-Reported Pain in Young Adults With Sickle Cell Disease: A Multicentre, Randomised Phase IIb Study
source: British Journal of Haematology
year: 2019
authors: Kanter J, Abboud MR, Kaya B, Nduba V, Amilon C, Gottfridsson C, Rensfeldt M, Leonsson-Zachrisson M
summary/abstract:Ticagrelor is an antiplatelet agent for adults with coronary artery disease. The inhibition of platelet activation may decrease the frequency of vaso-occlusion crisis (VOC) in sickle cell disease (SCD). The HESTIA2 study (NCT02482298) randomised 87 adults with SCD (aged 18-30 years) 1:1:1 to twice-daily ticagrelor 10, 45 mg or placebo for 12 weeks. Numerical decreases from baseline in mean proportion of days with patient-reported pain (primary endpoint) were seen in all three groups, as well as in pain intensity and analgesic use, with no significant differences between placebo and ticagrelor treatment groups. Plasma ticagrelor concentrations and platelet inhibition increased with dose. Adverse events were distributed evenly across groups and two non-major bleeding events occurred per group. Ticagrelor was well tolerated with a low bleeding risk, but no effect on diary-reported pain was detected. Potential effects on frequency of VOCs will need to be evaluated in a larger and longer study.
organization: Medical University of South Carolina, USA; American University of Beirut Medical Centre, Lebanon, Barts Health NHS Trust, UK; Kenya Medical Research Institute, Kenya; IMED Biotech Unit, Sweden; AstraZeneca R&D, SwedenDOI: 10.1111/bjh.15646
read more
+myBinderRelated Content
-
Acute Chest Syndrome – A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=wRzTQfhG...
-
Roland B. Scott Memorial Symposium: I Want Somebody to LoveRoland B. Scott Symposium on Sickle Cell...
-
Mistrust of Pediatric Sickle Cell Disease Clinical Trials ResearchINTRODUCTION: Sickle cell disease (SCD) ...
-
Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Fin...BACKGROUND AND PURPOSE: The recommended ...
-
Eileen Hansbury, MSEileen Hansbury is a Physician Assistant...
-
Only 21% of Kids with ADHD and SCD Are Treated for Attention DeficitA study of children with sickle cell dis...
-
Statement from FDA Commissioner on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.